KR890002401A - 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 표현 벡타 및 재조합 숙주 및 그의 제약상 용도 - Google Patents
재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 표현 벡타 및 재조합 숙주 및 그의 제약상 용도 Download PDFInfo
- Publication number
- KR890002401A KR890002401A KR1019870007966A KR870007966A KR890002401A KR 890002401 A KR890002401 A KR 890002401A KR 1019870007966 A KR1019870007966 A KR 1019870007966A KR 870007966 A KR870007966 A KR 870007966A KR 890002401 A KR890002401 A KR 890002401A
- Authority
- KR
- South Korea
- Prior art keywords
- aprotinin
- microbially
- glu
- prepared
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 항상 아프로티닌 주역 유전자의 디자인을 나타냄.
제2도는 4개의 블톡(알파, 베타, 감마, 델타)으로 되는 합성유전자의 구성에 사용되는 올리고뉴클레오티드의 DNA 서열을 나타냄, 제2b도는 15위치에서 아미노산 변경의 암호가 되는 단편의 DNA 서열을 나타냄.
제3도는 함성 Glu-52-아프로티닌 유전자의 DNA 서열(EcoRI-BamHI, pRK 63.1.1의 부분 서열)을 나타냄.
Claims (23)
- 미생물적으로 제조한 아프로티닌 및 아프로티닌 동족체.
- 필요에 따라서 메티오닌을 제외한 임의의 자연적으로 발생하는 아미노산에 의해서 15위치에서 치환된, 미생물적으로 제조한 아프로티닌.
- 미생물적으로 제조한 아프로티닌 및 Arg-15-, Val-15-, Ile-15-, Leu-15, Phe-15-1, Gly-15-, Ser-15-,Tyr-15- 및 Ala-15-아프로티닌.
- 제2항에 있어서, 52위치에서 Glu, Leu, Val, Thr 또는 Ser에 의해 추가로 치환된, 미생물적으로 제조한 아프로티닌.
- 미생물적으로 제조한 Glu-52-아프로티닌.
- 미생물적으로 제조한 Val-15-Glu-52-아프로티닌.
- 미생물적으로 제조한 Ile-15-Glu-52-아프로티닌.
- 미생물적으로 제조한 Leu-15-Glu-52-아프로티닌.
- 아프로티닌 및(또는) 아프로티닌 동족체를 암호화하는 주역유전자의 구성에 적합한 DNA 단편.
- 다음과 같은 군 및 그의 기능상 균등물 중에서 선택되는 DNA 단편.
- 다음과 같은 서열 및 그의 기능상 균등물에 의해 특징지워지는 DNA.
- 제11항에 있어서, 주로 Lys-15-토든이 Val-15-, Ile-15-, Leu-15-, Phe-15-1, Gly-15-, Ala-15-, Arg-52-, Ser-15-,Trp-15- 또는 Tyr-15-Glu-52-아프로티닌을 암호화하는 코든에 의해 치환된 DNA 서열로 되는 DNA.
- 제11항에 및 제12항 중 어느 하나의 항에 있어서, Glu-52-코든이 Leu, Val, Thr 또는 Ser의 암호가 되는 코든에 의해 치환된 DNA.
- 플라스미드PRK 63.1.1,PRK 54.1.1,PRK 49.2.1 및PRK 48.1.1.
- 제1항 내지 제8항의 단백질 제조에 유용한 표현 플라스미드.
- PRK 48.1.1 및PRK 49.2.1로 되는 군 중에서 선택되는, 제5항 내지 제8항의 단백질 제조에 유용한 표현 플라스미드.
- 아프로티닌 및(또는) 아프로티닌 동족체의 암호가 되는 표현 운반자를 사용하여 형질 전환시킨 숙주세포.
- 아프로티닌 및(또는) 아프로티닌 동족체의 암호가 되는 표현 운반자를 사용하여 형질 전환시킨 대장균.
- 제16항에 의한 표현 운반자를 사용하여 형질전환시킨 대장균.
- 제16항에 의한 표현 운반자를 사용하여 형질전환시킨 대장균 RP 1△M15(ATCC 번호 34102).
- 미생물적으로 제조한 아프로티닌 및(또는) 아프로티닌 동족체를 함유하는 제약 조성물.
- 미생물적으로 제조한 아프로티닌 및(또는) 아프로티닌 동족체의 약제 제조 용도.
- 제9항에 의한 DNA단편의 아프로티닌 및(또는) 아프로티닌 동족체를 암호화하는 유전자 구성 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB08607523A GB2188322A (en) | 1986-03-26 | 1986-03-26 | Aprotinin and analogues thereof produced by a recombinant host |
GB8607523 | 1986-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR890002401A true KR890002401A (ko) | 1989-04-10 |
KR960007194B1 KR960007194B1 (ko) | 1996-05-29 |
Family
ID=10595278
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870002715A KR950000302B1 (ko) | 1986-03-26 | 1987-03-25 | 아프로티닌 및 아프로티닌 동족체의 제조 방법 |
KR1019870007966A KR960007194B1 (ko) | 1986-03-26 | 1987-07-22 | 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 발현 벡타 및 재조합 숙주 및 그의 제약상 용도 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019870002715A KR950000302B1 (ko) | 1986-03-26 | 1987-03-25 | 아프로티닌 및 아프로티닌 동족체의 제조 방법 |
Country Status (15)
Country | Link |
---|---|
US (1) | US4894436A (ko) |
EP (1) | EP0238993B1 (ko) |
JP (1) | JP2537507B2 (ko) |
KR (2) | KR950000302B1 (ko) |
CN (1) | CN1018793B (ko) |
AT (1) | ATE123301T1 (ko) |
AU (1) | AU600475B2 (ko) |
CA (1) | CA1338309C (ko) |
DE (1) | DE3751324D1 (ko) |
DK (1) | DK151687A (ko) |
ES (1) | ES2073390T3 (ko) |
FI (1) | FI94876C (ko) |
GB (1) | GB2188322A (ko) |
IL (1) | IL81964A (ko) |
ZA (1) | ZA872181B (ko) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2188933A (en) * | 1986-04-10 | 1987-10-14 | Bayer Ag | Expression vectors for production of polypeptides, method for enhanced expression of polypeptides, hosts containing the expression vectors, products manufactured thereby |
US5654176A (en) * | 1987-05-28 | 1997-08-05 | Amrad Corporation Limited | Fusion proteins containing glutathione-s-transferase |
DE3724570A1 (de) * | 1987-06-27 | 1989-01-05 | Bayer Ag | Human-aprotinin, dessen lys-rest in position 15 gegen einen anderen protogenen aminosaeurerest ausgetauscht ist |
DK225488D0 (da) * | 1988-04-26 | 1988-04-26 | Novo Industri As | Polypeptid |
US5591603A (en) * | 1987-08-28 | 1997-01-07 | Novo Nordisk A/S | Process for preparing aprotinin and aprotinin analogs in yeast cells |
ATE103930T1 (de) * | 1988-03-07 | 1994-04-15 | Ciba Geigy Ag | Modifizierte proteine. |
US5180667A (en) * | 1988-03-07 | 1993-01-19 | Ciba-Geigy Corporation | Genes encoding eglin C mutants |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US20060134087A1 (en) * | 1988-09-02 | 2006-06-22 | Dyax Corp. | ITI-D1 Kunitz domain mutants as hNE inhibitors |
US7413537B2 (en) | 1989-09-01 | 2008-08-19 | Dyax Corp. | Directed evolution of disulfide-bonded micro-proteins |
DE3930522A1 (de) * | 1989-09-13 | 1991-03-21 | Bayer Ag | Rekombinante aprotinin-varianten - gentechnisches verfahren zur mikrobiellen herstellung von homogen prozessierten aprotinin-varianten sowie die therapeutische anwendung derselben |
US5231010A (en) * | 1989-09-13 | 1993-07-27 | Bayer Aktiengesellschaft | Recombinant aprotinin variants genetically engineered process for the microbial preparation of homogeneously processed aprotinin variants and the therapeutic use thereof |
WO1992006191A1 (en) * | 1990-09-28 | 1992-04-16 | Protein Engineering Corporation | Proteinaceous anti-dental plaque agents |
IL99585A0 (en) * | 1990-10-01 | 1992-08-18 | Novo Nordisk As | Aprotinin analogues,their production and pharmaceutical compositions containing them |
CA2055425A1 (en) * | 1990-11-13 | 1992-05-14 | Hideaki Morishita | Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same |
DK1820858T3 (da) | 1991-03-01 | 2009-11-02 | Dyax Corp | Kimært protein omfatende mikroprotein med to eller flere disulfidbindinger og udförelsesformer deraf |
DE69230061T2 (de) * | 1991-07-25 | 2000-01-05 | Oriental Yeast Co Ltd | Künstliches immunoglobulin-bindendes protein |
US5795954A (en) * | 1994-03-04 | 1998-08-18 | Genentech, Inc. | Factor VIIa inhibitors from Kunitz domain proteins |
US5786328A (en) * | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
US5780265A (en) * | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
US5824870A (en) * | 1995-11-06 | 1998-10-20 | Baszczynski; Chris | Commercial production of aprotinin in plants |
AU5187698A (en) * | 1996-12-06 | 1998-06-29 | Cancerforskningsfondet Af 1989 | Inhibition of invasive remodelling |
FR2774988B1 (fr) * | 1998-02-16 | 2000-05-05 | Commissariat Energie Atomique | Procede de purification de la prpres a partir d'un echantillon biologique et ses applications |
US7241730B2 (en) * | 1998-08-27 | 2007-07-10 | Universitat Zurich | Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides |
US7910550B2 (en) * | 2004-04-16 | 2011-03-22 | Stc.Unm | Human kunitz-type inhibitor with enhanced antifibrinolytic activity |
US7432238B2 (en) * | 2004-04-16 | 2008-10-07 | Stc.Unm | Human Kunitz-type inhibitor with enhanced antifibrinolytic activity |
US20060218667A1 (en) * | 2004-10-12 | 2006-09-28 | Vojdani Fakhrieh S | Plant-produced recombinant aprotinin and aprotinin variants |
ATE551422T1 (de) * | 2005-02-18 | 2012-04-15 | Angiochem Inc | Aprotininpolypeptide zum transport einer verbindung durch die blut-hirn-schranke |
CN100406558C (zh) * | 2005-06-14 | 2008-07-30 | 吉林圣元科技有限责任公司 | 制备重组抑酶肽的方法 |
WO2007076537A2 (en) | 2005-12-29 | 2007-07-05 | The Regents Of The University Of California | Methods and compositions related to mutant kunitz domain i of tfpi-2 |
WO2008110301A1 (de) * | 2007-03-13 | 2008-09-18 | Bayer Schering Pharma Aktiengesellschaft | Aprotinin-varianten mit verbesserten eigenschaften |
DE102007056231A1 (de) | 2007-09-08 | 2009-03-12 | Bayer Healthcare Ag | Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI) |
US20180223026A1 (en) * | 2015-07-31 | 2018-08-09 | Rohm And Haas Company | Oligomer seed for synthesis of unimodal acrylic bead particles |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3309501A1 (de) * | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | Plasmid-vektoren zur klonierung, identifizierung und expression von genen |
AU560584B2 (en) * | 1983-07-28 | 1987-04-09 | Bayer Aktiengesellschaft | Homologues of aprotinin |
DE3410437A1 (de) * | 1984-03-22 | 1985-09-26 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von proteinen |
DE3583361D1 (de) * | 1984-06-14 | 1991-08-08 | Ucp Gen Pharma Ag | Verfahren zur herstellung von thrombin-inhibitoren. |
WO1986000337A1 (fr) * | 1984-06-19 | 1986-01-16 | Transgene S.A. | DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION |
DE3429430A1 (de) * | 1984-08-10 | 1986-02-20 | Hoechst Ag, 6230 Frankfurt | Gentechnologisches verfahren zur herstellung von hirudin und mittel zur durchfuehrung dieses verfahrens |
DE3588249T2 (de) * | 1984-08-16 | 2004-05-06 | Savient Pharmaceuticals, Inc. | Methode zur Herstellung von menschlichen Wachstumshormonen |
DE3523701A1 (de) * | 1985-07-03 | 1987-01-08 | Bayer Ag | Verfahren zur herstellung von proteinen und polypeptiden |
GB2188933A (en) * | 1986-04-10 | 1987-10-14 | Bayer Ag | Expression vectors for production of polypeptides, method for enhanced expression of polypeptides, hosts containing the expression vectors, products manufactured thereby |
-
1986
- 1986-03-26 GB GB08607523A patent/GB2188322A/en not_active Withdrawn
-
1987
- 1987-03-11 AU AU69901/87A patent/AU600475B2/en not_active Ceased
- 1987-03-18 EP EP87103942A patent/EP0238993B1/de not_active Expired - Lifetime
- 1987-03-18 ES ES87103942T patent/ES2073390T3/es not_active Expired - Lifetime
- 1987-03-18 AT AT87103942T patent/ATE123301T1/de not_active IP Right Cessation
- 1987-03-18 DE DE3751324T patent/DE3751324D1/de not_active Expired - Fee Related
- 1987-03-23 US US07/029,501 patent/US4894436A/en not_active Expired - Lifetime
- 1987-03-23 IL IL81964A patent/IL81964A/xx not_active IP Right Cessation
- 1987-03-24 CA CA000532864A patent/CA1338309C/en not_active Expired - Fee Related
- 1987-03-24 FI FI871288A patent/FI94876C/fi not_active IP Right Cessation
- 1987-03-25 KR KR1019870002715A patent/KR950000302B1/ko not_active IP Right Cessation
- 1987-03-25 DK DK151687A patent/DK151687A/da not_active Application Discontinuation
- 1987-03-25 ZA ZA872181A patent/ZA872181B/xx unknown
- 1987-03-26 CN CN87102412A patent/CN1018793B/zh not_active Expired
- 1987-03-26 JP JP62072938A patent/JP2537507B2/ja not_active Expired - Lifetime
- 1987-07-22 KR KR1019870007966A patent/KR960007194B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
GB2188322A (en) | 1987-09-30 |
EP0238993A2 (de) | 1987-09-30 |
KR960007194B1 (ko) | 1996-05-29 |
ES2073390T3 (es) | 1995-08-16 |
ATE123301T1 (de) | 1995-06-15 |
KR870009025A (ko) | 1987-10-22 |
EP0238993A3 (en) | 1989-03-22 |
CN1018793B (zh) | 1992-10-28 |
JP2537507B2 (ja) | 1996-09-25 |
AU6990187A (en) | 1987-10-01 |
IL81964A (en) | 1993-07-08 |
CA1338309C (en) | 1996-05-07 |
ZA872181B (en) | 1987-12-30 |
DK151687D0 (da) | 1987-03-25 |
FI871288A0 (fi) | 1987-03-24 |
FI871288A (fi) | 1987-09-27 |
FI94876B (fi) | 1995-07-31 |
GB8607523D0 (en) | 1986-04-30 |
DK151687A (da) | 1987-09-27 |
US4894436A (en) | 1990-01-16 |
IL81964A0 (en) | 1987-10-20 |
JPS637794A (ja) | 1988-01-13 |
KR950000302B1 (ko) | 1995-01-13 |
FI94876C (fi) | 1995-11-10 |
DE3751324D1 (de) | 1995-07-06 |
CN87102412A (zh) | 1987-10-07 |
AU600475B2 (en) | 1990-08-16 |
EP0238993B1 (de) | 1995-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890002401A (ko) | 재조합 숙주로부터 제조한 아프로티닌 동족체, 그의 표현 벡타 및 재조합 숙주 및 그의 제약상 용도 | |
Waterfield et al. | Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus | |
Shepard et al. | A single amino acid change in IFN-β 1 abolishes its antiviral activity | |
EP0146354A2 (en) | Recombinant gamma interferons and pharmaceutical compositions containing them | |
FI904951A0 (fi) | Vaevnadsplasminogenaktivatorderivat. | |
Grant et al. | Biosynthesis of an insulin precursor by islet tissue of cod (Gadus callarias) | |
NZ230974A (en) | Osteogenic protein preparations and dna coding for such proteins | |
ATE123949T1 (de) | B-ketten-analoge des von blutplättchen abstammenden wachstumsfaktors und verfahren zu deren homogener herstellung. | |
DE3650645T2 (de) | Antigene Proteine und diese enthaltende Impfstoffe zur Verhütung von Kokzidiose | |
GR3020060T3 (en) | Modified proteins, modified interferons, alphas and beta, phosphorylated proteins and analogues, DNA sequences, applications and uses thereof | |
DK610888D0 (da) | Cardiodilatinfragmentet, fremgangsmaade til fremstilling deraf samt dets anvendelse | |
Bennett et al. | Isolation and analysis of human parathyrin in parathyroid tissue and plasma Use of reversed-phase liquid chromatography | |
DE59108947D1 (de) | Neues menschliches, rekombinantes interferon gamma | |
Wingfield et al. | Preparation and characterization of bovine growth hormones produced in recombinant Escherichia coli | |
STEWART et al. | Synthetic parathyroid hormone-like protein-(1–74): Biochemical and physiological characterization | |
SE8801723D0 (sv) | Fibronectin binding protein as well as its preparation | |
Kobayashi et al. | Purification and characterization of bullfrog growth hormone | |
IL88378A (en) | Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them | |
Oleinikov et al. | Escherichia coli ribosomal protein L7/L12 dimers remain fully active after interchain crosslinking of the C-terminal domains in two orientations. | |
Boulton et al. | The third variant of human myoglobin showing an unusual amino acid substitution: 138 (H16) arginine→ tryptophan | |
Dautrevaux et al. | Partial structure of beef myoglobin | |
Unit et al. | Parathyroid hormone, bovine, for bioassay: draft report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |